Chemical Stock Quietly Diversifying into Animal Health and CDMO to Keep on Your Radar

Synopsis: A fine chemicals major built on pharmaceuticals and crop protection is now looking beyond both, betting on animal health, personal care, and specialty chemicals to power its next growth cycle. Years of regulatory setbacks and pricing pressure pushed management to rethink its playbook, and the shift is now starting to show up in both strategy and numbers.

This company has long relied on two primary sectors: pharmaceutical APIs and crop protection chemicals, navigating through fluctuating market conditions influenced by global pricing and regulatory challenges. As competition in these traditional areas escalates, the firm is now exploring new, higher-margin opportunities. The critical inquiry remains whether this strategic diversification will successfully overcome the stagnation in growth experienced in recent years.

With a market capitalization of Rs. 2,932 crore, the shares of Hikal Limited were trading at Rs. 238 per share, with a 52-week range of Rs. 355 to Rs. 146, and they are trading at a P/E of approximately 81x.

Reducing Dependence on Agrochemicals

The crop protection industry has spent the last few years working through punishing inventory corrections, aggressive Chinese pricing, and structural overcapacity. While Hikal’s standalone Crop Protection revenue managed to stabilize flat at ₹692 crore in FY26 (matching FY25 but down significantly from its historical high of ₹908 crore in FY23), its full-year segmental EBIT fell from ₹79 crore to ₹51 crore. 

To mitigate this cyclical volatility, the company is systematically channeling its technological and manufacturing infrastructure away from commoditized legacy lines into steadier, higher-margin vectors: Animal Health, Personal Care, and Specialty Chemicals 

Animal Health Could Become a Meaningful Growth Engine

Hikal has already completed validation of all products under a long-term contract with a global multinational animal health company and is now moving into the commercial phase. Management says enquiries are picking up from customers across Europe, the US, and Japan, and the company is targeting a business of over Rs 500 crore within the next four to five years. It’s early days, but the direction of travel is clear from a niche intermediate supplier to a differentiated CDMO partner in animal health.

New Businesses Set to Contribute From FY27

Commercialization in personal care and specialty chemicals is progressing, with management guiding that these segments should start contributing meaningfully to revenue from FY27 onwards. For a company that has largely been a two-segment story, this represents a genuine attempt to widen its revenue base rather than simply chase volume growth in existing lines.

A Bigger Push Toward High-Margin CDMO

The “China+1” sourcing structural tailwind continues to yield results, triggering an aggressive transformation in Hikal’s product mix. In Q4 FY26, CDMO surged to 55% of Pharmaceuticals revenue (up from 49% in Q4 FY25), while Crop Protection CDMO footprint hit an outstanding 74% in the same quarter (up from 62% in the previous year’s quarter). 

This transition is further underscored by a major tactical asset realignment: management took a ₹47 crore non-cash impairment asset charge in Q4 to retire an older, underutilized multipurpose agrochemical block at Panoli. This facility is being completely re-engineered into an advanced pharmaceutical and animal health line. This move serves a dual purpose, capturing higher-margin contract manufacturing business while effectively derisking new product rollouts away from its Bangalore site, which is currently resolving a US FDA warning letter. 

Investing in Future-Ready Technology

Over the last 12–15 months, Hikal has commissioned a high-potency laboratory and expanded the R&D centre in Pune, along with a new pilot plant at its Panoli facility. These investments are now operational and are aimed at strengthening the company’s position in complex, differentiated chemistries, including HPAPI and ADC-related work. 

A dedicated HPAPI manufacturing facility is planned for FY28, and management has also said it wants to deepen its presence in newer markets like Japan, Brazil, and South Korea. Alongside this, DMF filings are expected to rise to 5–6 annually, up from 2–3 historically, pointing to a stronger long-term product pipeline in the pharmaceuticals business.

Better Product Mix Driving Margin Recovery

Rather than chasing revenue growth alone, Hikal appears focused on shifting its mix toward more specialized, higher-value products. That approach is starting to show in the numbers: Q4 FY26 EBITDA margin came in at 20.3%, up sharply from 16.8% in Q3 FY26 and better than the 12.9% EBITDA margin for full-year FY26. Quarterly EBITDA also rose to Rs 105 crore on revenue of Rs 519 crore, aided by a recovery in both Pharmaceuticals and Crop Protection after a soft first half.

Investor Verdict

Hikal’s FY26 wasn’t easy; full-year revenue slipped year-on-year, and profitability took a hit from one-off exceptional items. But the Q4 rebound, along with a clear pivot toward Animal Health, CDMO, and specialty segments, suggests management is trying to build a steadier, less cyclical business than what investors have seen in recent years.

Whether this diversification actually translates into sustained earnings growth will depend on execution, how quickly the newer segments scale, and how soon the pharma business clears its regulatory overhang. For now, the direction of change looks deliberate rather than accidental.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Chemical Stock Quietly Diversifying into Animal Health and CDMO to Keep on Your Radar appeared first on Trade Brains.